clinical trial Archives | Be Korea-savvy

Home / Posts tagged clinical trial

SLT (CognivAiD™) Improves Memory and Cognition in Individuals With Mild Cognitive Impairment: Clinical Trial Results

Investigator-initiated clinical trial of SLT (CognivAiD™) for mild cognitive impairment, led by Western Sydney University’s NICM Health Research Institute. Trial results reported that CognivAiD™ significantly improved key cognitive domains of episodic memory and executive function, and was well-tolerated. SINGAPORE, Nov. 09, 2023 (Korea Bizwire) – Moleac, a biopharmaceutical company pioneering innovative therapeutics in neurology, announced promising [...]

Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series

SHANGHAI, China and REDWOOD CITY, Calif., March 15 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus” ), today announced the presentation of positive results and biomarker analysis from the pivotal study “CHOICE-01” (clinicaltrials.gov identifier# NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as [...]

CoImmune Announces Positive Results from Phase 1/2 Clinical Trial of Allogeneic CAR-CIK Cells in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia

DURHAM, N.C., Dec. 15 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that results from a Phase 1/2 clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company’s chimeric antigen receptor (CAR) modified cytokine induced killer (CIK) cell platform, demonstrated sustained [...]

Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive results of an interim analysis of overall survival from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus standard-of-care chemotherapy [...]

TrialScope Atlas Helps Sponsors Reduce Risk, Manage the Complicated Global Clinical Trial Disclosure Process

NEW YORK, Oct. 26 (Korea Bizwire) – Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, has launched TrialScope Atlas, a single, searchable dashboard that automates clinical trial disclosure and consolidates a concise set of relevant regulations. Clinical trial sponsors are under increased pressure to maintain regulatory disclosure compliance, for several reasons: The EU [...]

Covicept Therapeutics Initiates a Phase 2 Clinical Study with PJS-539, an Oral Small Molecule for the Treatment of Patients with COVID-19 (SARS-CoV-2)

San Diego, USA, Oct. 6 (Korea Bizwire) – Covicept Therapeutics, an antiviral drug development company, announced today that a double-blind, placebo-controlled Phase 2 trial of PSJ-539 has been initiated and has begun enrolling patients with mild-to-moderate COVID-19. PSJ-539 has the potential to become a best-in-class small molecule for the treatment of COVID-19 patients and also has potential [...]

Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 16 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive interim results from the pivotal study “JUPITER-06” (NCT03829969), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with chemotherapy as a first-line [...]

Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

WALTHAM, Mass., Sept. 10 (Korea Bizwire) — Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 has provided a [...]

TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial

EDMONTON, Alberta, Aug. 31 (Korea Bizwire) — Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of first patient in the LidERA Breast Cancer (TRIO045) trial, a Phase 3 randomized, multi-center, open-label global clinical trial of adjuvant endocrine therapy, giredestrant (GDC-9545) sponsored by F. Hoffmann-LaRoche. Giredestrant is an oral selective [...]

SK Bioscience Kicks Off Phase 3 Clinical Trial of its COVID-19 Vaccine Candidate

SEOUL, Aug. 30 (Korea Bizwire) — South Korean drugmaker SK Bioscience Co. said Monday it has begun the phase three clinical trial of its COVID-19 vaccine candidate. GBP510, under development by SK Bioscience, a unit of the country’s No. 2 family-controlled conglomerate SK Group, was administered to the first participant. It comes nearly three weeks [...]